SHR-1139

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameSHR-1139
Drug Alias NameSHR-1139SHR1139
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Interleukin-23 subunit p19Anti-Interleukin-36 receptor
TargetsInterleukin-23 subunit p19Interleukin-36 receptor
Therapy Area/IndicationsPlaque psoriasisPsoriasisPyoderma Gangrenosum +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangdong Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Hengrui Pharmaceutical Co LtdAtridia Pty LtdShandong First Medical University
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisPyoderma Gangrenosum +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A